NCT00671268

Evaluation of Safety and Efficacy of Specific Immunotherapy With Recombinant Major Allergens of Timothy Grass Pollen Adsorbed Onto Aluminium-hydroxide in Patients With IgE-mediated Allergic Rhinoconjunctivitis +/- Controlled Asthma

Multicentre, Multinational Randomised DBPC Clinical Trial for Evaluation of Safety and Efficacy of Specific Immunotherapy With Recombinant Major Allergens of Timothy Grass Pollen Adsorbed Onto Aluminium-hydroxide in Patients With IgE-mediated Allergic Rhinoconjunctivitis +/- Controlled Asthma

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 256 (actual)
• Sponsor: Allergopharma GmbH & Co. KG · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

Efficacy and Safety from a high-dosed subcutaneous recombinant preparation

Conditions

• Rhinoconjunctivitis

Interventions

Type	Name	Description
BIOLOGICAL	AL0704rP	strict subcutaneous
BIOLOGICAL	Placebo	strict subcutaneous

Timeline

• Start date: 2008-03-01
• Primary completion: 2012-03-01
• Completion: 2013-03-01
• First posted: 2008-05-05
• Last updated: 2013-11-08

Locations

1 site across 1 country: Germany